{"title": "PDF", "author": "PDF", "url": "https://www.hrsa.gov/sites/default/files/hrsa/advisory-committees/vaccines/fda-update-dec-2021.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "1 Advisory Commission on Childhood Vaccines (ACCV) Jay Slater, MD Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food and Drug Administration December 2, 2021Pfizer BioNTech COVID -19 Vaccine Authorized for Use in Children 5 through 11 Years of Age October 29, 2021 -FDA authorized the emergency use of Pfizer -BioNTech COVID -19 Vaccine for the prevention of COVID -19 to include children 5 through 11 years of age. For this age group, the Pfizer -BioNTech COVID -19 Vaccine is supplied in multiple dose vials with orange caps and labels with orange borders and is administered intramuscularly as a primary series of 2 doses (0.2 mL each) 3 weeks apart. The Fact Sheet for Healthcare Providers Administering Vaccine is available at https://www.fda.gov/media/153714/download . The Fact Sheet for Recipients and Caregivers is available a https://www.fda.gov/media/153717/download . FDA convened its Vaccines and Related Biological Products Advisory Committee on this topic on October 26, 2021. 2September 2021 Pfizer BioNTech COVID -19 Vaccine -Authorization of Booster Dose for Certain Populations September 22, 2021 -FDA amended the Emergency Use Authorization (EUA) for the Pfizer -BioNTech COVID -19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series to individuals as follows: 65 years of age and older 18 through 64 years of age at high risk of severe COVID -19 18 through 64 years of age whose frequent institutional or occupational exposure to SARS -CoV-2 puts them at high risk of serious complications of COVID -19 including severe COVID -19. FDA convened its Vaccines and Related Biological Products Advisory Committee on this topic on September 17, 2021.3October 2021 Use of a Booster Dose for COVID -19 Vaccines October 20, 2021 -FDA amended the EUAs for COVID -19 vaccines to allow for the use of a single booster dose as follows: The use of a single booster dose of Moderna COVID -19 Vaccine that may be administered at least 6 months after completion of the primary series to individuals: 65 years of age and older, 18 through 64 years of age at high risk of severe COVID -19 and 18 through 64 years of age with frequent institutional or occupational exposure to SARS -CoV-2. The use of a single booster dose of Janssen COVID -19 Vaccine that may be administered at least 2 months after completion of the single - dose primary regimen to individuals 18 years of age and older. The use of each of the available COVID -19 vaccines as a heterologous booster dose in eligible individuals following completion of primary vaccination with a different available COVID -19 vaccine. 4October 2021 Use of a Booster Dose for COVID -19 Vaccines continued To clarify that a single booster dose of the Pfizer - BioNTech COVID -19 Vaccine may be administered at least 6 months after completion of the primary series to individuals 18 through 64 years of age with frequent institutional or occupational exposure to SARS -CoV-2. FDA convened its Vaccines and Related Biological Products Advisory Committee on October 14 and 15, 2021 to discuss the administration of a single booster dose for the Moderna COVID -19 Vaccine and Janssen COVID -19 Vaccine respectively. 5November 2021 FDA Expands Eligibility for Use of a Single Booster November 19, 2021 -FDA amended the EUA for both the Moderna and Pfizer -BioNTech COVID -19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA -authorized or approved COVID - 19 vaccine. FDA amended the EUA for the Janssen COVID -19 Vaccine authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with a different authorized or approved COVID -19 vaccine. 6Vaxneuvance Not previously reported -Vaxnuevance was approved in July 2021. Indication and Usage -for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 33F in adults 18 years of age and older. The vaccine is manufactured by Merck Sharpe & Dohme Corp. 7FDA COVID -19 Website FDA has a website dedicated to its COVID -19 activities, including FDA's pandemic response activities pertaining to vaccines, testing, therapeutics, and devices. The website is frequently updated and is a resource for the public, including healthcare providers and industry. "}